Compare TransMedics Group Inc (TMDX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? TransMedics Group Inc trades at $77.65 (market cap $2.74B), while YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M). The key difference: TransMedics Group Inc is far larger — about 7.5× YieldMax Universe Fund of Option Income ETFs's market cap, and TransMedics Group Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| TMDX | YMAX | |
|---|---|---|
Market Cap | $2.74B | $364M |
Volume | 949,331 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $150.42 | $12.98 |
52-Week Low | $61.99 | $7.27 |
Typical Hold Time | 24 Days | 56 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
YMAX trades at $7.53, down 1.83% on the day, with a bearish technical signal from moving averages. The ETF maintains weekly dividend distributions but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues, though the fund's structure as a fund-of-funds adds additional cost layers that impact returns.
The outlook remains cautious due to structural concerns and persistent share price decline despite high yield. Investment opportunity exists for income-focused investors willing to accept principal erosion risks, while the primary risk involves unsustainable distribution policy and compounding fees affecting long-term total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
